NCT05485818 - Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

November 18, 2021

Conditions

Acute Myocardial Infarction

Interventions

DRUG

Low Dose

12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）

DRUG

Middle Dose

12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）

DRUG

High Dose

12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）

OTHER

Placebo

15 subjects will be randomly assigned to the placebo for 7 days

Trial Locations (1)

Unknown

Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Beijing Northland Biotech. Co., Ltd.

INDUSTRY